Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Znomics has announced a collaborative research program with Oregon Health & Science University and Thomas Scanlan, director of its Chemical Biology Program, to design and develop pre-clinical compounds to treat diseases such as rheumatoid arthritis, asthma and inflammatory bowel syndrome.
Subscribe to our email newsletter
Under the research agreement, Znomics will fund the program and will have the option to exclusively license the rights to the discoveries.
With this collaboration, the company has met its objective this year of establishing three de novo drug discovery programs with the goal of having three pre-clinical lead compounds in different disease areas in 2010.
The programs announced in the second quarter of 2008 include a drug discovery program in obesity and a collaborative drug discovery program to develop compounds for the treatment of T-cell diseases, including leukemia, lymphoma and autoimmune disorders.
Richard Sessions, CEO of Znomics, said: “This is an important new therapeutic program for Znomics. Dr Scanlan has a proven record of designing new compounds that have progressed from the university setting into commercial development and clinical studies. We’re extremely pleased to have a research chemist of Tom’s caliber collaborating with us.”